Navigation Links
INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs

Replacing Both Ventricles with the Total Artificial Heart Eliminates Complications Including Right Heart Failure

Tucson, Ariz. (Vocus) May 12, 2009 -- According to INTERMACS data recently published in SynCardia’s 2008 Annual Report, the SynCardia temporary CardioWest™ Total Artificial Heart has a bridge-to-transplant rate of 72% at 6 months. This is double the bridge-to-transplant rate for Biventricular Assist Devices (BiVADS) at 36% and Left Ventricular Assist Devices (LVADs) at 27% (see Chart 1).

Unlike BiVADs and LVADs which assist the heart ventricle(s), the Total Artificial Heart replaces both dying heart ventricles. This eliminates complications caused by a dying heart including right native heart failure.

According to INTERMACS, 8% of BiVAD patients and 10% of LVAD patients experience right heart failure (see Chart 2). These patients often require treatment with inotropes and/or implantation of a right ventricular assist device. Total Artificial Heart patients are not subject to right native heart failure because the dying heart ventricles have been removed.

INTERMACS is the US national registry for patients with mechanical circulatory support devices that treat advanced heart failure. By applying uniform definitions and standards, INTERMACS levels the playing field for all mechanical circulatory support devices. INTERMACS tracks patient survival, adverse events and cause of death over time by patient profile, device and device category.

INTERMACS was created as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA) and the United Network for Organ Sharing (UNOS) among others.

Originally designed as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for patients dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

The SynCardia Total Artificial Heart is the first and only FDA, Health Canada and CE Mark approved Total Artificial Heart in the world. There have been more than 790 implants of the Total Artificial Heart, accounting for more than 160 patient years of life on the device.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Total Artificial Heart Patient 3rd in the World to Receive Dual Transplants
2. Extra payments to Medicare Advantage plans to total $11.4 billion in 2009
3. Swine Flu Cases Now Total 7: CDC
4. NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
5. SynCardia Introduces New 12-lb Freedom Discharge Driver Designed to Provide Quality 'Lifestyle' for Total Artificial Heart Patients
6. Squeezing Calories? New Study Finds That Low-Fat Popcorn Before Lunch Does Not Increase Total Calorie Intake
7. FCP Announces Total Healthcare Integration Solution (THIS) Powered by TIBCO
8. Closing Open Heart Surgery: Saint Josephs Performs Georgias First Totally-Closed, Beating Heart Bypass Surgery
9. Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement
10. MEDRAD Multi Vendor Service Launches TotalRepair(SM) on Select Ultrasound Probes
11. Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008
Post Your Comments:
Related Image:
INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: